PRIMARY STUDY
Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS)
Key Findings: This study measured the oral bioavailability of β-Caryophyllene (BCP) in a self-emulsifying drug delivery system (SEDDS) when given to healthy subjects. It was deemed safe and well-tolerated, and the SEDDS system effectively increased the bioavailability BCP.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 24
Study Result: Positive
Research Location(s): Germany, Switzerland, United States
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, PPAR - Alpha, PPAR - Gamma, PPARs
Ligands Studied: Serotonin
Dosage: BCP (100 mg single dose)
Route of Administration: Oral (Ingestion)
Citation: Mödinger Y, et al. Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS). Molecules. 2022; 27:(unknown pages). doi: 10.3390/molecules27092860
Authors: Mödinger Y, Knaub K, Dharsono T, Wacker R, Meyrat R, Land MH, Petraglia AL, Schön C
